Kragerø, Norway
Kragerø, Norway

Time filter

Source Type

News Article | April 27, 2017
Site: globenewswire.com

Weifa ASA (OSE: WEIFA) had record first-quarter revenues in 2017 on higher sales within the categories: pain relief, cough & cold products and dermatology, which includes the Asan portfolio. Total revenues for the quarter was NOK 99.6 million, representing an all-organic growth of 3.6% compared with the same period of 2016. EBITDA was NOK 21.2 million (NOK 16.5 million) for the first quarter after NOK 1.0 million (NOK 5.5 million) in cost of employee options and other costs. The EBITDA margin adjusted for these costs was 22.3% (22.8%). Weifa's portfolio of long-established brands maintained a high market share in all key segments during the quarter. "We maintained a steady pace into 2017 with record first-quarter revenues. The launch of Nazamér Menthol and Paracetduo effervescent tablets extended our innovation track record, which together with rising demand for our main products are a key driver for our long-term growth," says CEO Kathrine Gamborg Andreassen. Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen will represent the company. The presentation will also be webcast live and can be accessed directly from: http://webtv.hegnar.no/presentation.php?webcastId=51528850 http://www.weifa.no/webcast/ Questions may be submitted live during the presentation. Please find the report and presentation for the first quarter enclosed. The report and presentation will also be made available on www.weifa.no . For further information, please contact: Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no


News Article | April 28, 2017
Site: globenewswire.com

Weifa ASA (OSE: WEIFA), please find attached the Annual Report for 2016 for Weifa ASA. The Annual Report will also be made available on www.weifa.no. For further information, please contact:


News Article | April 28, 2017
Site: globenewswire.com

Weifa ASA (OSE: WEIFA), please find attached the Annual Report for 2016 for Weifa ASA. The Annual Report will also be made available on www.weifa.no. For further information, please contact:


News Article | April 21, 2017
Site: globenewswire.com

Weifa ASA (OSE: WEIFA), Norway's leading consumer health company, will release its first quarter 2017 results on Thursday 27 April 2017. The results will be presented by Weifa's CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. Following the presentation, there will be a Q&A session. The presentation will be held in English. The presentation will also be webcast live and can be accessed directly from http://webtv.hegnar.no/presentation.php?webcastId=51528850or http://www.weifa.no/webcast.Questions may be submitted live during the presentation. The quarterly report and the presentation materials will be available on www.weifa.com/Investor/ and www.newsweb.no, as well as on news wires. For further information, please contact: Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no


News Article | February 28, 2017
Site: globenewswire.com

(Oslo, 28 February 2017) Saga Tankers ASA ("Saga", OSE: SAGA) reported a net asset value (NAV) of NOK  784 million at the end of the fourth quarter of 2016, corresponding to NOK 2.95  per share, excluding minority interests and with Vallhall valued at book value. By the end of fourth quarter, Saga had a cash balance of NOK 439 million and no long term debt, except the real estate financing related to the holding in Vallhall. The positive development in available for sale reserves of NOK 9.7 million, classified as other comprehensive income, is the net effect of positive return on investment in Pareto Bank and negative effect on investments in Vistin Pharma ASA and Nel ASA. Financial assets are adjusted to market value according to IFRS. SD Standard Drilling Plc is  (46.2% ownership) an associate and recognized according to the equity method. Vallhall Arena is a subsidiary. For further information, please contact: By end of first quarter the largest investments in Saga Tankers ASA were: NEL ASA is the first dedicated hydrogen company on the Oslo Stock Exchange. Since its foundation in 1927, NEL Hydrogen has a proud history of development and continual improvement of hydrogen plants. Nel's main products are hydrogen production plants for industry and energy applications, hydrogen fueling stations for the transport sector, and power-to-gas/power-to-power solutions for the renewable industry. The company also holds a number of patents related to tests for early detection and diagnosis of diseases. For further information: www.nelhydrogen.com Vistin Pharma is a Norwegian pharmaceutical company producing Active Pharmaceutical Ingredients (APIs) and solid dosage forms for the global pharmaceutical industry. The company has key positions in the Metformin and Opioids markets, and a strong foundation for creating a highly efficient CMO business (contract manufacturing of tablets).  Solid growth potentials exist in all the business segments. The spin-off from Weifa facilitates new growth opportunities due to a narrower business scope, increased visibility and being able to pursue own strategic agendas without the risk of compromises across business units. Pareto Bank is a leading niche player within project financing. The bank has main focus on financing of real estate, securities and corporate, shipping and offshore. Pareto Bank is a compact organization with 35 employees, short decision lines, and an efficient credit decision process. The main geographical real estate exposure is in Oslo and Akershus. Financing of securities is mainly related to listed stocks. Pareto Bank also finance small and medium size corporate, primarily related to a project or M&A. Further Pareto Bank finance some segments within the shipping and offshore industry. Vallhall Arena is Oslo's largest indoor arena, centrally located at Helsfyr in Oslo with good public transportation connections. Several hotels are also located close to the arena. The arena was built in 2001. The cost was approximately NOK 130 million whereof NOK 80 million was funded by debt and NOK 55 million was funded by equity from owners. The arena has about 9 000 square meter expanse. The arena is well-known for its high quality indoor soccer hall and is used by school children, as well as professionals. The arena is also leased out for events such as exhibitors, seminars, concerts and other events requiring facilities that Vallhall Arena can offer. Having sold all initial rig contracts, the strategy of the company has changed to being an investment company within the oil and gas service sector. Main assets are currently cash holdings and investments within the PSV segment. The company currently owns 100% of three large-size PSV's and have ownership in 13 mid-size PSV's bringing the total fleet of party and/or fully owned vessels to 16. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


News Article | February 28, 2017
Site: globenewswire.com

The fourth quarter results recorded by the Norwegian pharmaceutical company Vistin Pharma ASA (OSE: VISTIN) were negatively affected by an unscheduled stop in metformin production, as reported on in November. Provisions related to redundancies and re-organisation within the Company's tablet manufacturing facility also affected the figures. The adjusted EBITDA for the fourth quarter ended at minus NOK 1.5 million, while the full-year figure showed a positive NOK 29.5 million. "Whilst our financial figures for the fourth quarter reflect some unexpected costs and provisions related to our CMO tablet manufacturing operational excellence programme, we maintain our positive outlook for the Company. We continue to experience growth in all our markets, and we are investing in increased capacity. Together with our continuous focus on operational efficiency, we expect Vistin Pharma to continue to deliver profitable growth in the years to come," says CEO Kjell-Erik Nordby. The adjusted EBITDA for the fourth quarter include an impact of approximately NOK 5.1 million from the lower metformin volumes available for sale, caused by the temporary stop in production. Excluded from adjusted EBITDA for the quarter is a NOK 5.8 million provision for redundancies relating to the ongoing CMO cost savings programme, and NOK 1.7 million in one-off costs relating to the reactor failure. Vistin Pharma recorded total revenue and income of NOK 93.6 million in the fourth quarter of 2016, compared to NOK 104.5 million in the fourth quarter of 2015. The 2015 figure included net proceeds of NOK 8.7 million from a settlement relating to the business transfer from Weifa AS. Vistin Pharma was spun off from Weifa in 2015. Revenue from metformin business was 32.5 million in the fourth quarter, down 22 percent compared to the corresponding quarter in 2015. The unscheduled stop affected the quarterly results by approximately NOK 10 million in lost sales. Opioids revenue in the fourth quarter was NOK 30.4 million, compared to NOK 20.1 million in the fourth quarter of 2015. The total volume sold during the quarter was significantly higher than the volume sold in the fourth quarter of 2015 for both API and tablets. Revenue for the CMO segment was NOK 30.7 million, slightly down from the fourth quarter of 2015 (NOK 33.9 million). The Company's financial position remains strong, with a cash position of NOK 89.4 million as of 31 December. Total equity was NOK 186.6 million, compared to NOK 183.9 million at year-end 2015.  The equity ratio stood at 66.8 percent (71.0 percent). Vistin Pharma holds no interest-bearing debt. Vistin Pharma will hold a presentation today at 08:30 CET at Carnegie AS, Fjordalleen 16, Oslo, Norway. CEO Kjell-Erik Nordby and CFO Gunnar Manum will represent the Company. The presentation will be webcast live and can be accessed directly from http://webtv.hegnar.no/presentation.php?webcastId=44475356, Please find the report and presentation for the fourth quarter 2016 enclosed. The report and presentation will also be made available on www.vistin.com. For further information, please contact: Kjell-Erik Nordby CEO +47 91 36 42 80 Vistin Pharma is a Norwegian pharmaceutical company producing Active Pharmaceutical Ingredients (APIs) and solid dosage forms for the global pharmaceutical industry. The Company has key positions in the Metformin and Opioids markets, and a strong foundation for creating a highly efficient Contract Manufacturing tablet production (CMO) business.  Solid growth potentials exist in all the business segments. With more than 65 years of pharmaceutical industry experience, Vistin Pharma has built significant capacity and expertise as an API provider. The Company has more than 140 highly qualified employees and two manufacturing facilities in Kragerø, Norway. Both facilities are certified according to current Good Manufacturing Practice (cGMP) and successfully inspected by the US Food and Drug Administration (FDA) in 2014. Vistin Pharma's headquarter is in Oslo, Norway. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


News Article | February 16, 2017
Site: globenewswire.com

Weifa ASA (OSE: WEIFA) had record fourth quarter and full-year revenues in 2016 on higher sales of the main categories: pain relief, cough & cold products and nutraceuticals, as well as the addition of the Asan portfolio. Total revenues for the quarter was NOK 114.5 million, representing an increase of 17 percent compared with the same period a year earlier. Organic growth was 5.4%, after adjusting for Asan. "Our quarterly revenues exceeded NOK 100 million for the first time in the fourth quarter, even before including Asan. We experienced growing demand for our main product categories and positive impact from the innovative new products we have recently launched," says CEO Kathrine Gamborg Andreassen. EBITDA was NOK 27.7 million (NOK 22.1 million) for the fourth quarter after NOK 1.1 million (NOK 2.4 million) in cost of employee options and other costs. The EBITDA margin adjusted for these costs was 25.2% (25.1%). Weifa's portfolio of long-established brands maintained a high market share in all key segments during the quarter. Revenues for the full year 2016 was NOK 399.7 million (NOK 332.5 million), an increase of 20% from 2015. EBITDA was NOK 80.4 million (NOK 65.6 million) for the fourth quarter after NOK 8.9 million (NOK 7.3 million) in cost of employee options and other costs. The EBITDA margin adjusted for these costs was 22.3% (21.9%). Weifa expects to launch Asan in Finland in 2017 after signing a distribution agreement with Midsona Finland Oy in the fourth quarter. A further strengthening of Nordic position is planned in 2017 after securing the rights to commercialise a new and unique product line based on a patented fixed-combination pain management solution containing ibuprofen and paracetamol. "We remain focused on our growth strategy. The new distribution and licensing agreements we have signed in recent weeks will drive Weifa's expansion in the Nordic region. At the same we time remain committed to strengthening the established brands and developing new innovative products", says Gamborg Andreassen. In line with Weifa's dividend policy of returning excess cash to shareholders, the board of directors proposes a dividend of NOK 1.50 per share to be paid in June 2017. Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen will represent the company. The presentation will also be webcast live and can be accessed directly from: http://webtv.hegnar.no/presentation.php?webcastId=44472366 http://www.weifa.no/webcast/. Questions may be submitted live during the presentation. Please find the report and presentation for the fourth quarter enclosed. The report and presentation will also be made available on www.weifa.no. For further information, please contact: Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no


This is a correction of the announcement from 07:30 16.02.2017 CET. Reason for the correction: Weifa ASA (OSE: WEIFA) had record fourth quarter and full-year revenues in 2016 on higher sales of the main categories: pain relief, cough & cold products and nutraceuticals, as well as the addition of the Asan portfolio. Total revenues for the quarter was NOK 114.5 million, representing an increase of 17 percent compared with the same period a year earlier. Organic growth was 5.4%, after adjusting for Asan. "Our quarterly revenues exceeded NOK 100 million for the first time in the fourth quarter, even before including Asan. We experienced growing demand for our main product categories and positive impact from the innovative new products we have recently launched," says CEO Kathrine Gamborg Andreassen. EBITDA was NOK 27.7 million (NOK 22.1 million) for the fourth quarter after NOK 1.1 million (NOK 2.4 million) in cost of employee options and other costs. The EBITDA margin adjusted for these costs was 25.2% (25.1%). Weifa's portfolio of long-established brands maintained a high market share in all key segments during the quarter. Revenues for the full year 2016 was NOK 399.7 million (NOK 332.5 million), an increase of 20% from 2015. EBITDA was NOK 80.4 million (NOK 65.6 million) for the fourth quarter after NOK 8.9 million (NOK 7.3 million) in cost of employee options and other costs. The EBITDA margin adjusted for these costs was 22.3% (21.9%). Weifa expects to launch Asan in Finland in 2017 after signing a distribution agreement with Midsona Finland Oy in the fourth quarter. A further strengthening of Nordic position is planned in 2017 after securing the rights to commercialise a new and unique product line based on a patented fixed-combination pain management solution containing ibuprofen and paracetamol. "We remain focused on our growth strategy. The new distribution and licensing agreements we have signed in recent weeks will drive Weifa's expansion in the Nordic region. At the same we time remain committed to strengthening the established brands and developing new innovative products", says Gamborg Andreassen. In line with Weifa's dividend policy of returning excess cash to shareholders, the board of directors proposes a dividend of NOK 1.50 per share to be paid in June 2017. Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen will represent the company. The presentation will also be webcast live and can be accessed directly from: http://webtv.hegnar.no/presentation.php?webcastId=44472366 http://www.weifa.no/webcast/. Questions may be submitted live during the presentation. Please find the report and presentation for the fourth quarter enclosed. The report and presentation will also be made available on www.weifa.no. For further information, please contact: Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no


News Article | February 16, 2017
Site: globenewswire.com

Reference is made to the 4th quarter 2016 report for Weifa ASA (the "Company") dated 16 February 2017. The Company hereby informs of the following key dates in connection with the proposed dividend: Trading exclusive of dividend ("ex date"):     31 May 2017 For further information, please contact:


News Article | February 16, 2017
Site: globenewswire.com

Reference is made to the 4th quarter 2016 report for Weifa ASA (the "Company") dated 16 February 2017. The Company hereby informs of the following key dates in connection with the proposed dividend: Trading exclusive of dividend ("ex date"):     31 May 2017 For further information, please contact:

Loading Weifa AS collaborators
Loading Weifa AS collaborators